In the pharmaceutical industry, peptides are trying to find their place between large and small molecules[1]. They currently represent 18% of global pipelines in phases 2 and 3[1]. There are more than 25 approved drugs and 280 candidates in development[3]. More than 1,200 clinical trials are underway, mainly focused on metabolic diseases and oncological disorders[3]. 45% of approved peptide drugs are indicated for metabolic diseases and diabetes[4]. Companies are overcoming the initial challenges through advanced synthesis technologies such as continuous SPPS, which reduces the mass intensity of the process by up to 50%[1]. Investments in peptides exceed $7 billion from the public and private sectors[3]. Notable partnerships include PeptiDream's $180 million deal with Novartis and $1 billion with Genentech[1].